Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Lyell Immunopharma (LYEL) FCF Margin: 2020-2025

Historic FCF Margin for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to -190,926.67%.

  • Lyell Immunopharma's FCF Margin fell 8768843.00% to -190,926.67% in Q3 2025 from the same period last year, while for Sep 2025 it was -403,743.90%, marking a year-over-year decrease of 15575660.00%. This contributed to the annual value of -266,980.33% for FY2024, which is 13899571.00% down from last year.
  • As of Q3 2025, Lyell Immunopharma's FCF Margin stood at -190,926.67%, which was up 55.89% from -432,825.00% recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's FCF Margin peaked at -92.69% during Q4 2022, and registered a low of -1,407,866.67% during Q1 2024.
  • Moreover, its 3-year median value for FCF Margin was -294,115.38% (2024), whereas its average is -393,688.52%.
  • As far as peak fluctuations go, Lyell Immunopharma's FCF Margin soared by 117,827,600bps in 2023, and later plummeted by 133,441,282bps in 2024.
  • Over the past 5 years, Lyell Immunopharma's FCF Margin (Quarterly) stood at -1,540.79% in 2021, then soared by 144,810bps to -92.69% in 2022, then slumped by 31,267,654bps to -312,769.23% in 2023, then tumbled by 11,710,350bps to -429,872.73% in 2024, then plummeted by 8,768,843bps to -190,926.67% in 2025.
  • Its last three reported values are -190,926.67% in Q3 2025, -432,825.00% for Q2 2025, and -785,485.71% during Q1 2025.